Search research articles
Contact Us
Filters
Showing results (271-280 of 442) with videos related to
Page
of 45
Sort By:
JCO Precision Oncology
|
May 6, 2026
<i>NTRK</i> Gene Fusions: A Compendium of Fusion Partners and Tumor Types
Soo-Ryum Yang, Matteo Repetto, Erin R Rudzinski, et al.
Targeted Oncology
|
September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
Kathleen N Moore, David S Hong, Manish R Patel, et al.
Oncotarget
|
December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomes
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
Jennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials
Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2012
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors
David S Hong, Daniel W Bowles, Gerald S Falchook, et al.
Cancer
|
June 19, 2025
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors
Timothy A Yap, Olivier Rixe, Capucine Baldini, et al.
Oncotarget
|
February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
Ishwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Biorxiv : the Preprint Server for Biology
|
March 17, 2025
Inhibitors of oncogenic Kras specifically prime CTLA4 blockade to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
Krishnan K Mahadevan, Ana S Maldonado, Bingrui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
David S Hong, Patricia LoRusso, Omid Hamid, et al.
Page
of 45
Search research articles
Search
Showing results (271-280 of 442) with videos related to
Sort By:
Page
of 45
JCO Precision Oncology
|
May 6, 2026
<i>NTRK</i> Gene Fusions: A Compendium of Fusion Partners and Tumor Types
Soo-Ryum Yang, Matteo Repetto, Erin R Rudzinski, et al.
Targeted Oncology
|
September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
Kathleen N Moore, David S Hong, Manish R Patel, et al.
Oncotarget
|
December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomes
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
Jennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials
Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2012
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors
David S Hong, Daniel W Bowles, Gerald S Falchook, et al.
Cancer
|
June 19, 2025
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors
Timothy A Yap, Olivier Rixe, Capucine Baldini, et al.
Oncotarget
|
February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
Ishwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Biorxiv : the Preprint Server for Biology
|
March 17, 2025
Inhibitors of oncogenic Kras specifically prime CTLA4 blockade to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
Krishnan K Mahadevan, Ana S Maldonado, Bingrui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
David S Hong, Patricia LoRusso, Omid Hamid, et al.
Page
of 45